Home Page

mRNA Vaccines

With India’s first and the World’s third mRNA vaccine, Gennova ushers in a future

where emerging diseases can be met with speed, precision and unparalleled

efficacy. Our mRNA vaccine is the first mRNA vaccine to be stable at 2 to 8˚ C,

addressing the unmet need globally.
Cardiovascular

ST-Elevation Myocardial Infarction (STEMI) occurs due to occlusion in one or more of

the coronary arteries supplying blood to the heart. Reperfusion therapy with single bolus

tenecteplase (Elaxim®) in a timely manner improves blood flow in the infarct related coronary

artery and reduces mortality. Elaxim®, a 3rd generation thrombolytic has impacted more than

200,000 lives in the last decade. This cost effective innovation has revolutionized the STEMI

patient management in India and other emerging markets.
Neurology

Acute Ischemic Stroke (AIS) is a medical emergency. It occurs due to arterial occlusion and is

associated with very high morbidity and mortality. Intravenous thrombolysis with tenecteplase

(Tenectase®), a 3rd generation agent, approved by Drug Controller General of India improves

outcomes in patients with AIS. Tenectase® is safe, easy to administer and cost effective,

making it an attractive alternative for reperfusion therapy in stroke.
Nephrology

Vintor 2000, 3000, 4000, 6000, 10000, 20000 and 40000

Erythropoietin, used for patients suffering with Chronic Renal Failure, has been saving lives

of millions of patients since its launch in India in 2007
Oncology

G-CSF and GM-CSF from Gennova are supplementing multiple cancer treatment for over

a decade now. PEGylated long lasting version of G-CSF provides the same medical benefit

but with a significantly reduced dose regimen. Our PEGylated asparaginase has been saving

lives of hundreds of children suffering from ALL Compared to L-asparaginase, PEGasparagase

has lower immunogenicity and reduced dosing.

Transforming Healthcare

One of our greatest assets is our appreciation and understanding of the complexity of a problem and dedicated focus to develop a long lasting solution instead of looking for a quick fix. We realized early on that we will not be able to develop, deliver and survive in the competitive market of biotechnology if we do not innovate across all the required scientific platforms. This is what separates us from the rest of the traditional biotechnology companies interested in making biosimilar.

Company Highlights

Gene to Market

9 Commercialized
Bio-therapeutics
3 products – market leader in India
2 novel products

Platform Technology

Patented manufacturing process
Readily scalable
AI guided innovation in
Bio-manufacturing

Potential

2 patents with market exclusivity
Unmet market need
Facility under development as per USFDA norms
Global clinical trials for 3 products in next 12-18 months
Quick launch in global market

Team

A strong leadership team, experienced in successful global collaboration and taking product from lab to market

Pipeline

Biologics
Vaccines
Next-Gen therapeutics

Product Milestones

Infrastructure

Other than our marketing strategies our investment in the technological development of the infrastructure gives us an edge over others. We have experience and expertise that allows us to develop innovative and cost effective products because of the cutting edge technology backed by research.

Global Collaborations

“Many factors play an important role in the process of Transforming Healthcare, and one of the most important is that we cannot innovate in isolation. We have to have collaborations.”

– Dr. Sanjay Singh, CEO, Gennova Biopharmaceuticals Ltd.

Gene to Market

We have a team of experienced and capable scientists and technocrats who have developed capabilities across scientific, manufacturing, regulatory, clinical and business arenas that have made it successful in the Indian market.
The experience and capabilities will facilitate the expansion of business in the global market for our current and pipeline products.